Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Metastatic castration-resistant prostate cancer

Oncology Today

Oncology Today—June 8, 2026

This week’s Oncology update highlights regulatory approvals, priority review…

Onco_background

Oncology Today—April 6, 2026

This week’s Oncology update highlights regulatory progress, late-stage clinical…

Onco_background

Oncology Today—March 16, 2026

This week’s Oncology update highlights regulatory progress, pivotal-intent…

Onco_background

Oncology Today—March 2, 2026

This week’s Oncology update highlights major regulatory approvals,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
LucidScope AI Audit Analyses
Public Health News
Monthly Strategic Roundups
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Immunology Strategic Roundup | June 9–July 14, 2026
AI perception of Lipid-Lowering Therapies | LucidScope AI Visibility Audit
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Hematology Strategic Roundup | June 8–July 10, 2026

Tags

4-OH-PLA all-cause mortality APDS biopharma devices BRAF V600E metastatic colorectal cancer breast cancer research Cardiovascular Research Cell Metabolism Centanafadine Cytokinetics DiaCardia Ebola vaccine financing FSGS Genitourinary Cancers GENIXCURE Global Biosimilar Week Henlius Biotech Hevaxin HR+/HER2- breast cancer Human papillomavirus–related diseases Kinaset Therapeutics LDL Longevity Market marketing strategy medical AI Mindera Health minimal residual disease neuroblastoma Nonmelanoma Skin Cancer NSLC NTRK fusion-positive tumors Oncology News online patient communities Prime Medicine psoriatic arthritis RSV Vaccine Samsung SoftOx sweetener Targeted Therapy vapendavir Weight Loss Science Yescarta Ziftomenib

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Immunology Strategic Roundup | June 9–July 14, 2026
AI perception of Lipid-Lowering Therapies | LucidScope AI Visibility Audit
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Hematology Strategic Roundup | June 8–July 10, 2026

TAGS

4-OH-PLA all-cause mortality APDS biopharma devices BRAF V600E metastatic colorectal cancer breast cancer research Cardiovascular Research Cell Metabolism Centanafadine Cytokinetics DiaCardia Ebola vaccine financing FSGS Genitourinary Cancers GENIXCURE Global Biosimilar Week Henlius Biotech Hevaxin HR+/HER2- breast cancer Human papillomavirus–related diseases Kinaset Therapeutics LDL Longevity Market marketing strategy medical AI Mindera Health minimal residual disease neuroblastoma Nonmelanoma Skin Cancer NSLC NTRK fusion-positive tumors Oncology News online patient communities Prime Medicine psoriatic arthritis RSV Vaccine Samsung SoftOx sweetener Targeted Therapy vapendavir Weight Loss Science Yescarta Ziftomenib

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy